About Foresight Biotherapeutics
Foresight Biotherapeutics is a Healthcare company based in New York (United States) founded in 2008 by Jason Stein, and was acquired by Shire in August 2015. Therapies in ophthalmology and otolaryngology are developed using PVP-I technology. Foresight Biotherapeutics has raised $17 million across 2 funding rounds from investors including Takeda Pharmaceuticals. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified.
Company details
Foresight Biotherapeutics was founded in 2008 in New York, United States, as a clinical-stage company focused on drug development in ophthalmology and otolaryngology. The PVP-I platform is utilized to combine povidone-iodine, a broad-spectrum antiseptic, with anti-inflammatory agents. Product candidates include FST-100, a topical eye drop for adenoviral conjunctivitis, and FST-201 for acute otitis media. The company was acquired by Shire in 2015.
- Total Equity Funding$17M (USD)
in 2 rounds
- Latest Funding Round$15M (USD), Series B
Nov 2013
- Investors
- Acquired byShire
(Aug 2015)
Funding Insights of Foresight Biotherapeutics
Foresight Biotherapeutics has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in November 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 2
- Last Round Series B — $15M
- First Round $2M
(Jul 2011)
All 2 funding rounds of Foresight Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2013 | $15M | Series B | – | – | – |
| Jul 2011 | $2M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Foresight Biotherapeutics
Foresight Biotherapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Rare disease treatments are developed by a specialty biopharmaceutical firm. | 1986 | shire.com | Dublin, Ireland |
Investor details for Foresight Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Foresight Biotherapeutics
1 people are tracked at Foresight Biotherapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jason Stein | Co-Founder & Director | Leadership |
Complete people profiles for Foresight Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Foresight Biotherapeutics
4 dated milestones of Foresight Biotherapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Foresight Biotherapeutics is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series B, of $15.0M.
- Exit Acquired by Shire.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Foresight Biotherapeutics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Foresight Biotherapeutics
Foresight Biotherapeutics was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Foresight Biotherapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Foresight Biotherapeutics is a funded company, having raised a total of $17M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Jul 2011.
Foresight Biotherapeutics was founded in 2008 in New York, United States, as a clinical-stage company focused on drug development in ophthalmology and otolaryngology. The PVP-I platform is utilized to combine povidone-iodine, a broad-spectrum antiseptic, with anti-inflammatory agents. Product candidates include FST-100, a topical eye drop for adenoviral conjunctivitis, and FST-201 for acute otitis media. The company was acquired by Shire in 2015.
Foresight Biotherapeutics has 1 investor. Key investors include Takeda Pharmaceuticals.
Yes. Foresight Biotherapeutics was acquired by Shire in August 2015.